This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
MicroPort Scientific Corporation undertakes no obligation to update any of the statements. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.
For more information, please refer to: We believe the future of orthopaedic implant surgery will include advanced elements of artificial intelligence and augmented reality.
All other trademarks and trade names referred to in this release are the property of orthorecon business plan respective owners. The system has orthorecon business plan developed in close collaboration with internationally recognized experts in the shoulder field, providing an innovative and practical solution to the operating room.
Food and Drug Administration rejected its Augment Bone Graft product for use as an alternative in foot and ankle fusion procedures.
The regulatory agency said it would be willing to re-evaluate the use of Augment Bone Graft after a new clinical trial that evaluates the use of the product in a high-risk target population, where the use of an autograft transfer would be clinically warranted. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others.
The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
BMO Capital Markets analyst Joanne Wuensch said Wright Medical still has a healthy franchise of biologic products that are growing by double digits — even without the regulatory approval of Augment Bone Graft for use in foot and ankle fusion procedures.
Also, very importantly, this will provide our employees with enhanced opportunities for career growth and development. Wright Medical Group N.
Palmisano has previously said the sale will allow Wright Medical to focus on its breakthrough biologic opportunities as a high-growth extremities company. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.
Even if Augment Bone Graft never gets approval, Palmisano said Wright Medical still plans to focus on the medical-device extremities business. You can enter multiple email addresses separated by commas Message: With its simple and intuitive interface, this virtual surgical plan is seamlessly translated into the operating room on the day of surgery offering the potential for reduced surgical time, better outcomes and less inventory.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain.
Before the surgery, the surgeon can optimize the surgical plan adapted to the patient to choose the best implant from a range of possibilities.
The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. He added that the company hopes to replace revenue lost from the MicoPort deal as soon as possible.
Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Software-enhanced solutions are the future, and with the acquisition of IMASCAP, we have the opportunity to take a significant lead in this area.
Distributed by Public, unedited and unaltered, on 19 June He said the company is eying mergers and acquisitions, including overseas.
This is a highly differentiated, enabling technology for the shoulder and has a number of potential applications to enhance our PROPHECY planning for ankles as well. IMASCAP software system is the only system in the world allowing orthopaedic surgeons complete independence for planning, with nothing more than image data provided by CT scan of the patient.
The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. We look forward to an exciting future as part of Wright Medical. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
The software allows the surgeon to automatically conceive a surgical guide adapted particularly to the patient anatomy, which permits the surgeon to implant the prosthesis in a position that closely matched the software plan. The product already is being used in overseas markets including Australia and Canada, she said.
The surgeon is able to visualize the shoulder in 3D and rotate through the complete range of motion in any direction. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.After closing, the OrthoRecon business will continue to be headquartered in Arlington, Tennessee and Ted Davis, who is currently president of Wright’s OrthoRecon business, will lead the MicroPort Orthopedic business.
Find all Local Office Blogs posts tagged with university of memphis. + Retirement Plan Services + Plan Sponsor Resources.
(b) Plan Resources + Retirement Services. in January following MicroPort Scientific’s acquisition of Wright Medical Technology, Inc.’s global OrthoRecon business. technology business. The first of these — an increasing emphasis on value and the concomitant need to demonstrate improved outcomes — was something we explored in our Pulse of the industry.
report. The following year, we discussed the second transformative trend: patient-empowering. Aug 12, · In June, Wright Medical announced the sale of its hip- and knee-implants business to OrthoRecon, a unit of Shanghai-based MicroPort Scientific.
Jun 19, · Wright Medical Group, Inc. and MicroPort Scientific Corporation Enter Into Definitive Agreement Under Which MicroPort Will Acquire Wright's OrthoRecon Business Transaction Transforms.
MicroPort Acquires OrthoRecon Business from Wright Medical Technologies MicroPort Orthopedics, headquartered in Arlington, TN, is a global medical device company specializing in the design, manufacture and marketing of .Download